# Strategic Report, Directors' Report and

**Financial Statements** 

for the Year Ended 30 June 2021

<u>for</u>

Catalent CTS (Wales) Limited



COMPANIES HOUSE

1 6 MAR 2022

EDINBURGH MAILBOX

# Contents of the Financial Statements for the Year Ended 30 June 2021

	Pag
Company Information	1
Strategic Report	2
Directors' Report	3
Statement of Directors' Responsibilities	4
Independent Auditor's Report	5
Balance sheet	7
Statement of Changes in Equity	8
Notes to the Financial Statements	9

# Catalent CTS (Wales) Limited

# Company Information for the Year Ended 30 June 2021

**DIRECTORS:** 

Ricci Whitlow

R De Nobel (resigned 28 June 2021)
Guy Dewil (appointed 28 June 2021)

Thomas Castellano (appointed 28 June 2021)

**SECRETARY:** 

R De Nobel (resigned 28 June 2021)

Guy Dewil (appointed 28 June 2021)

**REGISTERED OFFICE:** 

Frankland Road

Blagrove Swindon Wiltshire, England SN5 8YG

**REGISTERED NUMBER:** 

03577928 (England and Wales)

**AUDITOR:** 

Ernst & Young LLP 144 Morrison Street

Edinburgh EH3 8EX

# Strategic Report for the Year Ended 30 June 2021

The Directors present their strategic report for the year ended 30 June 2021.

Whillow

### Results and performance

The result for the period after taxation amounted to £nil (2020 £Nil).

### Review of the business

The Company operates an investment holding Company. Its key investment is in the trading Company Catalent CTS (Edinburgh) Limited, whose principal activity is that of contract packaging and distribution of clinical trial drug materials.

### Future developments

The directors have assessed the impact of the COVID-19 pandemic in detail in the Directors' Report.

ON BEHALF OF THE BOARD:

15 March 2022

### <u>Directors' Report</u> for the Year Ended 30 June 2021.

The Directors present their report with the financial statements of the Company for the year ended 30 June 2021.

### RESULTS AND DIVIDENDS

The result for the year after taxation amounted to £Nil (2020 £Nil). The Directors do not recommend a final dividend (2020 £Nil)

### **DIRECTORS**

The Directors who held office during the period were as follows:

R Whitlow

R De Nobel (resigned 28 June 2021)

G Dewil (appointed 28 June 2021)

T Castellano

None of the Directors in office during the year held any beneficial interests in the share capital of the Company during the year.

### **GOING CONCERN**

The company's business activities are set out in the Strategic Report.

The Company has limited cash flows activity outside of the Catalent Inc ("Catalent") group. The company is reliant on the support of Catalent to satisfy the going concern assumption.

The group trades in an industry that has been listed by all governments as essential businesses to continue trading during the pandemic. Demand for clinical supply services the company has remained stable to increasing. On the basis of their assessment of the Company's financial position and relevant enquiries, the directors have a reasonable expectation that the Company will be able to access the support of Catalent as and when required and thus be able to continue in operational existence for the foreseeable future. Thus, they continue to adopt the going concern basis of accounting in preparing the annual financial statements.

The Company continues to receive all necessary financial backing from its parent Company, Catalent Inc.

### STATEMENT AS TO DISCLOSURE OF INFORMATION TO AUDITOR

Shullows

So far as the Directors are aware, there is no relevant audit information (as defined by Section 418 of the Companies Act 2006) of which the Company's auditor are unaware, and each Director has taken all the steps that he ought to have taken as a Director in order to make himself aware of any relevant audit information and to establish that the Company's auditor are aware of that information.

### AUDITOR

A resolution to reappoint Ernst & Young LLP as auditor will be put to the members at the Annual General Meeting.

ON BEHALF OF THE BOARD:

15 March 2022

### STATEMENT OF DIRECTORS' RESPONSIBILITIES

The Directors are responsible for preparing the Strategic Report, Directors' Report and the financial statements in accordance with applicable law and regulations.

Company law requires the Directors to prepare financial statements for each financial year. Under that law the Directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under Company law the Directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the Company and of the results of the Company for that period. In preparing these financial statements, the Directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Company will continue in business.

The Directors are responsible for keeping adequate accounting records that are sufficient to show and explain the Company's transactions and disclose with reasonable accuracy at any time the financial position of the Company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

### Independent Auditor's Report to the Members of Catalent CTS (Wales) Limited

### Opinion

We have audited the financial statements of Catalent CTS (Wales) Limited for the year ended 30 June 2021 which comprise of the Income Statement, the statement of Other Comprehensive Income, the Balance Sheet, Statement of changes in equity and the related notes 1 to 11 including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards including FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" (United Kingdom Generally Accepted Accounting Practice).

In our opinion, the financial statements:

- give a true and fair view of the company's affairs as at 30 June 2021 and of its profit for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

### **Basis for opinion**

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion. Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of 12 months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report. However, because not all future events or conditions can be predicted, this statement is not a guarantee as to the company's ability to continue as a going concern.

### Other information

The other information comprises the information included in the annual report, other than the financial statements and our auditor's report thereon. The directors are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in this report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of the other information, we are required to report that fact.

We have nothing to report in this regard.

### Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the strategic report and the directors' report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the strategic report and directors' report have been prepared in accordance with applicable legal requirements. Matters on which we are required to report by exception

In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the strategic report or directors' report.

# Independent Auditor's Report to the Members of Catalent CTS (Wales) Limited (Continued)

# Opinions on other matters prescribed by the Companies Act 2006 (Continued)

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:

- adequate accounting records have not been kept or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of directors' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit.

### Responsibilities of directors

As explained more fully in the directors' responsibilities statement set out on page 4, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Explanation as to what extent the audit was considered capable of detecting irregularities, including fraud

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect irregularities, including fraud. The risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment by, for example, forgery or intentional misrepresentations, or through collusion. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below. However, the primary responsibility for the prevention and detection of fraud rests with both those charged with governance of the entity and management.

- We obtained an understanding of the legal and regulatory frameworks that are applicable to the company and determined that the most significant are those that relate to the reporting framework (FRS102 and companies Act 2006) and relevant tax compliance regulations in the UK. We also determined that there was no non-compliance with regulatory requirements.
- We understood how Catalent CTS (Wales) Limited is complying with those frameworks by making enquiries of management and those responsible for legal and compliance procedures. We confirmed our enquiries through our review of board minutes, regulatory correspondence and papers provided to the holding company. We assessed the susceptibility of the company's financial statements to material misstatement, including how fraud might occur by meeting with management to understand where they considered there was susceptibility to fraud. We also considered performance targets and their propensity to influence on efforts made by management to manage earnings. We considered the programmes and controls that the company has established to address risks identified, or that otherwise prevent, deter and detect fraud; and how senior management monitors those programmes and controls at a group level. Where the risk was considered to be higher, we performed audit procedures to address the identified fraud risk, management override of controls, specifically around revenue recognition.
- Based on this understanding we designed our audit procedures to identify non-compliance with such laws and regulations. Our procedures involved: journal entry testing, with a focus on manual journals and journals indicating large or unusual transactions based on our understanding of the business and enquiries of legal counsel and management. In addition, we completed procedures to conclude on the compliance of the disclosures in the financial statements and accounts with all applicable requirements.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at https://www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.

# Independent Auditor's Report to the Members of Catalent CTS (Wales) Limited (Continued)

## Use of our report

This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.

Erost & Yang LLP

Paul Copland (Senior statutory auditor) for and on behalf of Ernst & Young LLP, Statutory Auditor Edinburgh

16 March 2022

# Balance Sheet 30 June 2021

		20	21	20	20
	Notes	£	£	£	£
Investments	6		20,093,791		20,093,791
CURRENT ASSETS					
Debtors	7 _	28,318		28,318	
NET CURRENT ASSETS		_	28,318	-	28,318
TOTAL ASSETS LESS CURRENT LIABILITIES		-	20,122,109	,	20,122,109
CAPITAL AND RESERVES					
Called up share capital	8		2		2
Capital contribution reserve	9		39,306,340		39,306,340
Retained earnings	9	_	(19,184,233)	÷	(19,184,233)
SHAREHOLDERS' FUNDS		_	20,122,109	_	20,122,109

The financial statements were approved and authorised for issue by the Board of Directors on 15 March 2022 and were signed on its behalf by:

Killi Sullibor Ricci Whitlow - Director

Page | 8

# Statement of Changes in Equity for the Year Ended 30 June 2021

•	Called up share capital £	Retained earnings	Capital contribution reserve	Total equity £
Balance at 1 July 2019	2	(19,184,233)	39,306,340	20,122,109
Changes in equity		<u> </u>		
Balance at 30 June 2020	2	(19,184,233)	39,306,340	20,122,109
Changes in equity		, <u>.</u>	<del> </del>	<del> </del>
Balance at 30 June 2021	2	(19,184,233)	39,306,340	20,122,109

# Notes to the Financial Statements for the Year Ended 30 June 2021.

### 1. STATEMENT OF COMPLIANCE

Catalent CTS (Wales) Limited is a limited liability Company incorporated in England. The Registered Office is Frankland Road, Blagrove, Swindon, Wiltshire, England, SN5 8YG.

The Company's financial statements have been prepared in compliance with FRS 102 as it applies to the financial statements of the Company for the year ended 30 June 2021.

### 2. ACCOUNTING POLICIES

# Basis of preparing the financial statements

The financial statements have been prepared under the historical cost convention.

The financial statements of Catalent CTS (Wales) Limited were authorised for issue by the Board of Directors on 30 June 2021.

The financial statements have been prepared in accordance with applicable accounting standards. The financial statements are prepared in sterling which is the functional currency of the Company and rounded to the nearest pound.

### Going Concern

The Company has limited cash flows activity outside of the Catalent Inc ("Catalent") group. The company is reliant on the support of Catalent to satisfy the going concern assumption.

The group trades in an industry that has been listed by all governments as essential businesses to continue trading during the pandemic. Demand for clinical supply services the company has remained stable to increasing. On the basis of their assessment of the Company's financial position and relevant enquiries, the directors have a reasonable expectation that the Company will be able to access the support of Catalent as and when required and thus be able to continue in operational existence for the foreseeable future. Thus, they continue to adopt the going concern basis of accounting in preparing the annual financial statements.

The Company continues to receive all necessary financial backing from its parent Company, Catalent Inc.

## Financial reporting standard 102 - reduced disclosure exemptions

The Company has taken advantage of the following disclosure exemption in preparing these financial statements. As permitted by FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" no income and cash flow statement has been prepared as the Company is a wholly owned subsidiary of Catalent Inc, whose group financial statements includes a consolidated income and cash flow statement and is publicly available.

### Group financial statements

The financial statements present information about the Company as an individual undertaking and not about its group. The Company has taken advantage of the exemption from preparing consolidated accounts by virtue of section 401 of the Companies Act 2006, as it is a wholly owned subsidiary of Catalent Inc., in which the subsidiary undertaking is included.

A copy of the consolidated financial statements of Catalent Inc. can be obtained from Catalent Pharma Solutions, 14 Schoolhouse Road, Somerset, NJ 08873.

### Significant judgements and estimates

The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the amounts reported for assets and liabilities as at the balance sheet date and the amounts reported for revenues and expenses during the year. However, the nature of estimation means that actual outcomes could differ from those estimates.

# Notes to the Financial Statements - continued for the Year Ended 30 June 2021

### 2. ACCOUNTING POLICIES - continued

### Investments

Management assess for impairment on an annual basis and assessing whether there are any triggers of impairment identified. If a triggers are identified, a full impairment calculation is completed.

### Financial instruments

The Company has chosen to adopt the requirements of sections 11 and 12 of FRS102 in respect of the measurement and disclosure of financial instruments.

### Short-term debtors

Debtors with no stated interest rate and receivable or payable within one year are recorded at transaction price. Any losses arising from impairment are recognised in the income statement in other operating expenses.

The Company does not have any 'other' financial instruments.

### 3. STAFF COSTS

There were no staff costs for the year ended 30 June 2021 nor for the year ended 30 June 2020.

### 4. **DIRECTORS' EMOLUMENTS**

The Directors of the Company are also Directors of other group companies. The Directors do not believe that it is practicable to apportion their total remuneration between companies. The amounts are therefore disclosed in full in other group Company's financial statements.

Emoluments	2021 £	2020 £
Company contributions paid to defined contribution pension schemes	<u> </u>	<u></u> -
Members of defined contribution pension schemes	2021 No.	2020 No.

The remuneration of the highest paid Director was £Nil (2020: £Nil) including £Nil (2020: £Nil) of Company contributions paid to a defined contribution pension scheme. There were no directors based in the UK in 2021.

### 5. AUDITOR'S REMUNERATION

Fees in respect of the audit of the Company are borne by the subsidiary Company Catalent CTS (Edinburgh) Limited.

## Notes to the Financial Statements - continued for the Year Ended 30 June 2021

6.	INVESTMENTS	Subsidiary undertakings £
	COST	
	At 1 July 2020	
	and 30 June 2021	39,306,342
	IMPAIRMENT	
	At 1 July 2020	
	and 30 June 2021	19,212,551
	NET BOOK VALUE	
	At 30 June 2021	20,093,791
	At 30 June 2020	20,093,791

The Company's investments at the Balance Sheet date in the share capital of companies include the following:

Investment Catalent CTS (Edinburgh) Ltd	<b>Location</b> UK	Registered Office Frankland Road Blagrove, Swindon Wiltshire, England SN5 8YG	Direct/ Indirect Holding 100% Direct

7.	DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR	
		2021

	2021	2020
	£	£
Amounts owed by group undertakings	28,318	28,318

## 8. CALLED UP SHARE CAPITAL

The authorised, allotted and fully paid share capital of the Company consisted of:

Authorised 100,000 ordinary shares of £0.01 each	£ 	£ 1,000
Allotted, called up and fully paid 200 ordinary shares of £0.01	2021 £	2020 £
200 ordinary snares of £0.01		

### 9. RESERVES

Retained earnings - Distributable reserve includes all current and prior period retained profits and losses.

Capital redemption reserve - Non-distributable reserve which a capital contribution of £39,306,340 was received from the ultimate parent Company and is included within 'Capital contribution reserve'.

### Notes to the Financial Statements - continued for the Year Ended 30 June 2021

### 10. RELATED PARTY DISCLOSURES

The Company has taken advantage of exemption, under the terms of Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with wholly owned subsidiaries within the group.

All Directors and certain senior employees who have authority and responsibility for planning, directing and controlling the activities of the Company are considered to be key management personnel.

Key management personnel compensation in total for the year was £Nil (2020: £Nil). There were no directors based in the UK in 2021.

### 11. ULTIMATE PARENT COMPANY

The ultimate parent undertaking is Catalent Inc, which is incorporated in the United States of America. The Company's immediate parent undertaking is Catalent CTS UK Holding Limited.

A copy of the consolidated financial statements of Catalent Inc can be obtained from Catalent Pharma Solutions, 14 Schoolhouse Road, Somerset, NJ 08873.